The hierarchical structure of sections and sub-sections were incorrectly formatted in the final version of the article.
The bullet points starting at “In E. coli, expression of the AmpC…” are intended as sub-sections of “Enzymatic inactivation”, page 4, Aztreonam-avibactam.
The sections starting at “Alterations in iron transport systems.” are intended as sub-sections of “Resistance mechanisms”, page 5, Cefiderocol.
The sections starting at “A. baumannii:” are sub-subsections of the section “Alterations in iron transport systems”, page 6, Cefiderocol.
Similarly, the sections starting at “Reduced outer membrane permeability.” are sub-sections of “Resistance mechanisms”, page 7, Meropenem-vaborbactam.
The sections at “OmpK35 inactivation:” are sub-sections of the “K. pneumoniae”, page 7, Meropenem-vaborbactam.
Sections beginning at lines “Mutations in ddn” are sub-sections of “Resistance mechanisms”, page 8, Pretomanid.
Sections beginning at “Increased efflux pump expression” are sub-sections of “Resistance mechanisms”, page 8, Lefamulin.
Sections beginning at lines “Efflux pump overexpression” are sub-sections of “Resistance mechanisms”, page 9, Omadacycline.
Sections beginning at lines “Efflux pump overexpression” are sub-sections of “Resistance mechanisms”, page 9, Eravacycline.
Sections beginning at “Modification of target sites” are sub-sections of “Resistance mechanisms”, page 10, Plazomicin.
Sections beginning at “Enzymatic inactivation” are sub-sections of “Resistance mechanisms”, page 11, Rifamycin SV.
Sections beginning at “Target site modifications” are sub-sections of “General resistance mechanisms”, page 12, Quinolones and fluoroquinolones.
Sections beginning at “Increased efflux pump expression” are sub-sections of “Resistance mechanisms”, page 12, Delafloxacin.
There was a mistake in Table 2 as published. In line 2 of the table, regarding “Cefepime and enmetazobactam” antibiotic, the column “Main use” reports “HABP, cUTIs, and cIAIs”. The corrected Table 2 appears below, where “cIAIs” has been removed for that drug.
Table 2.
Antimicrobial drugs approved by FDA and/or EMA since 2017.
| Entry | Drug name | Approval year | Drug class (subclass) | Main use |
|---|---|---|---|---|
| 1. | Aztreonam and avibactam | 2024 EMA | β-lactams and BLICs Monobactam and non-β-lactam β-lactamase inhibitor | cUTIs, cIAIs, HABP, VABP, and Gram-negative blood stream infections with limited treatment options |
| 2. | Cefepime and enmetazobactam | 2024 FDA | β-lactams and BLICs Cephalosporin and β-lactamase inhibitor | HABP and cUTIs |
| 3. | Ceftobiprole | 2024 FDA | β-lactams and BLICs Cephalosporin | ABSSSI, CABP and SAB |
| 4. | Sulbactam and durlobactam | 2023 FDA | β-lactams and BLICs β-lactamase inhibitors | A. baumannii–calcoaceticus complex HABP and VABP in adult patients aged |
| 5. | Cefiderocol | 2019 FDA 2020 EMA |
β-lactams and BLICs Cephalosporin | cUTIs, HABP, VABP, and other serious Gram-negative infections with limited treatment options |
| 6. | Imipenem, cilastatin, and relebactam | 2019 FDA 2020 EMA |
β-lactams and BLICs Carbapenem, renal dehydropeptidase inhibitor, and β-lactamase inhibitor | cUTIs, cIAIs, and HABP/VABP |
| 7. | Meropenem and vaborbactam | 2017 FDA 2018 EMA |
β-lactams and BLICs Carbapenem and β-lactamase inhibitor | cUTIs, cIAIs, HAP/VAP, and bacteremia or other infections caused by CRE with limited treatment options |
| 8. | Pretomanid | 2019 FDA 2020 EMA |
Nitroimidazole | Pulmonary TB (MDR-TB and RR-TB) |
| 9. | Lefamulin | 2019 FDA 2020 EMA |
Pleuromutilin | CABP |
| 10. | Omadacycline | 2018 FDA | Tetracycline | ABSSSI, CABP |
| 11. | Eravacycline | 2018 FDA 2018 EMA |
Tetracycline | cIAIs |
| 12. | Plazomicin | 2018 FDA | Aminoglycoside | cUTIs |
| 13. | Rifamycin | 2018 FDA | Rifamycin | Travelers' diarrhea caused by non-invasive strains of Escherichia coli |
| 14. | Delafloxacin | 2017 FDA 2019 EMA |
Fluoroquinolone | ABSSSIs, CABP |
| 15. | Gepotidacin | 2025 FDA | Triazaacenaphthylenes | uUTI |
The original version of this article has been updated.
Footnotes
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.